Clinical management of cholestatic liver disease
- VernacularTitle:胆汁淤积性肝病的临床管理
- Author:
Yuecheng GUO
1
;
Xiaobo CAI
1
;
Lungen LU
1
Author Information
- Publication Type:Journal Article
- Keywords: Cholestasis; Ursodeoxycholic Acid; Obeticholic Acid
- From: Journal of Clinical Hepatology 2025;41(7):1246-1250
- CountryChina
- Language:Chinese
- Abstract: Cholestatic liver disease(CLD)is a group of hepatobiliary disorders caused by impaired bile production,secretion,or excretion.With the application of liquid biopsy,multi-parameter radiological examination,and genomics technology,significant progress has been made in the diagnosis and prognostic evaluation of CLD.At present,the therapeutic principles for CLD mainly focus on addressing the underlying causes and managing cholestasis,and commonly used drugs include ursodeoxycholic acid,S-adenosylmethionine,cholestyramine,fibrates,and obeticholic acid.Based on the latest clinical consensus statements and research advances in CLD,this article systematically elaborates on the clinical management strategies for CLD from the aspects of diagnosis,treatment,and prognostic evaluation.
